{"id":167829,"date":"2026-09-16T20:06:32","date_gmt":"2026-09-16T20:06:32","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/167829\/"},"modified":"2026-09-16T20:06:32","modified_gmt":"2026-09-16T20:06:32","slug":"novo-partners-with-anthropic-to-speed-up-drug-development-with-claude","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/167829\/","title":{"rendered":"Novo partners with Anthropic to speed up drug development with Claude"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Sept 16 (Reuters) &#8211; Novo Nordisk has partnered with Anthropic to use the AI giant&#8217;s Claude \u200cmodels to speed up discovery and development \u200cof new medicines, the companies said on Wednesday.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Here are more details:  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 \u200bThe Danish drugmaker will initially test Anthropic models and Claude Science in its research and development workflows, and address scientific problems where their joint capabilities can \u200chave the greatest \u2060impact, they said.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 &#8220;But beyond this, <a href=\"https:\/\/tech.yahoo.com\/ai\/\" data-ylk=\"slk:AI;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;AI&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" class=\"no-affiliate-link link\">AI<\/a> tools can also offer completely new scientific opportunities \u2060and aid reasoning and understanding of human biology and drug mechanics,&#8221; Novo CEO Mike Doustdar said.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 Drugmakers \u200bare increasingly \u200bturning to artificial intelligence \u200bto accelerate R&amp;D and \u200cimprove efficiency across their pipelines.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 The Wegovy maker will also use Anthropic&#8217;s frontier models to strengthen AI-driven software development.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 &#8220;By giving leading researchers access to safe, capable, and trusted frontier models, we can shorten research \u200ctimelines, improve outcomes, and discover \u200bmedicines and treatments that significantly \u200bimprove human life,&#8221; \u200bsaid Dario Amodei, CEO of Anthropic.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 \u200cMeanwhile, AI industry leaders are \u200bsplit over how \u200bfast companies should develop the increasingly powerful technology.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 Novo already uses Claude to automate trial \u200breport generation, and \u200ctrim timelines for patient documentation creation from \u200bmonths to minutes.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">(Reporting by Sriparna Roy in Bengaluru; \u200bEditing by Leroy Leo)  <\/p>\n","protected":false},"excerpt":{"rendered":"Sept 16 (Reuters) &#8211; Novo Nordisk has partnered with Anthropic to use the AI giant&#8217;s Claude \u200cmodels to&hellip;\n","protected":false},"author":2,"featured_media":167830,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[34067,33884,5032,272,7512],"class_list":["post-167829","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-anthropic","tag-claude","tag-development","tag-novo-nordisk","tag-research-and-development"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117282523472840355","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/167829","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=167829"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/167829\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/167830"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=167829"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=167829"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=167829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}